缬沙坦联合前列地尔治疗糖尿病肾病的临床疗效研究

Clinical efficacy of valsartan combined with alprostadil in treatment of diabetic nephropathy

目的探讨缬沙坦联合前列地尔治疗糖尿病肾病的临床疗效。方法选择2012年6月~2014年6月确诊的64例糖尿病肾病患者,全部患者按1∶1的比例完全随机分为研究组和对照组,每组32例,两组均予降糖、降压治疗,同时控制饮食及适量运动,对照组予缬沙坦片80 mg,每日1次,口服,连用4周,研究组同时加用前列地尔100μg,置入100 m L Na Cl溶液中静滴,每日1次,连用4周。比较两组的临床总有效率以及治疗前后BUN、UAER、SCr各项观察指标的变化。结果治疗4周后比较两组疗效,研究组的总有效率为93.75%,与对照组的71.88%比较,差异有统计学意义（P〈0.05）。两组BUN、UAER、SCr水平治疗后均较治疗前降低,且研究组治疗后BUN、UAER、SCr水平较对照组降低更显著（t=2.754、3.632、3.247,P〈0.05）。结论缬沙坦联合前列地尔可以提高糖尿病肾病的临床疗效,改善肾功能,安全性好,值得推广和应用。

Objective To investigate the clinical efficacy of valsartan combined with alprostadil in treating diabetic nephropathy. Methods A total of 64 cases of diabetic nephropathy patients diagnosed from June 2012 to June 2014 ac-cording to the ratio of 1：1 in all patients were randomly assigned to study group and control group, 32 cases in each group, two groups were treated with hypoglycemic, antihypertensive therapy, meanwhile with diet and proper exercise, control group was treated with valsartan tablets 80 mg, 1 time, oral daily, for 4 weeks, the study group combined with alprostadil in 100 mL NaCl, solution 100 μg, intravenous drip, 1 time a day, for 4 weeks. The total efficiency of the two groups before and after treatment, and BUN, UAER, SCr indexes change of two groups were compared. Results The treatment efficacy of the two groups were compared after 4 weeks, the total efficacy rate of the study group was 93.75%, compared with the control group＇s 71.88%, the difference was statistically significant （P〈0.05）. BUN, UAER, SCr levels of two groups were significantly lower after treatment, and the BUN, UAER, SCr levels of study group after treatment decreased more significantly than the control group, the difference was statistically significant （t=2.754, 3.632, 3.247, P〈0.05）. Conclusion Valsartancombined combined with alprostadil can improve the clinical curative effect of diabetic nephropathy, improve renal function, with good safety, and is worthy of promotion and application.